Logo

financial results

Amgen Spotlights Investigational Precision Oncology Candidates as Q1 Revenue Jumps 9 Percent
Premium

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

Pfizer Misses Revenue Expectations in Q1, but Invests Operational Savings in Oncology-Heavy Pipeline
Premium

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher manufacturer discounts.

AstraZeneca Anticipates Limited Effect of Tariffs, Reports Q1 Oncology Revenue Growth
Premium

The firm said it has begun to shift the few drugs made in Europe for the US to be manufactured domestically.

BMS Touts Significant Growth in Breyanzi Revenues in Q1 as Overall Revenues Drop
Premium

The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.

Merck Addresses Impact of Trump Tariffs Amid Slowing Keytruda Sales Growth
Premium

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its manufacturing.

Apr 24, 2025

Roche Sees Surging Phesgo Uptake Amid Steady Q1 Revenue Growth
Premium

Apr 15, 2025

J&J Hopes to Make Rybrevant-Lazcluze Standard Frontline Treatment in EGFR-Mutant NSCLC
Premium

Mar 20, 2025

Autolus Reports Steady Progress for Aucatzyl's US Launch, Anticipating European Approvals in 2025

Feb 12, 2025

Gilead Expects Continued Competitive Pressure in 2025 for Cell Therapy Products
Premium

Feb 6, 2025

AstraZeneca Optimistic About Phase III Camizestrant Data in 2025, Reports Strong Q4 Product Growth
Premium

Feb 6, 2025

Bristol Myers Squibb Focused on Opdivo SubQ Growth as Q4 Precision Product Sales Increase
Premium

Feb 5, 2025

Amgen Reports More Than $2B in Oncology Revenues in Q4

Feb 4, 2025

Merck Talks Up Pipeline Diversification as Demand for Keytruda, Facing Patent Expirations, Grows
Premium

Feb 4, 2025

Pfizer Reports 27 Percent Oncology Growth in Q4, Touts Progress in ADC and Breast Cancer Trials
Premium

Jan 31, 2025

Novartis Posts Strong Q4 Sales of Kisqali, Pluvicto

Jan 22, 2025

J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4

Nov 12, 2024

AstraZeneca Reports Q3 Revenue Growth for Precision Cancer Drugs Amid Ongoing China Investigations
Premium

Nov 7, 2024

Gilead Sciences Focuses on New Multiple Myeloma CAR T Amid Flat Q3 Cell Therapy Sales
Premium

Oct 31, 2024

Merck Talks Up Pipeline Diversification as Keytruda Sales Still Comprise 45 Percent of Q3 Revenues
Premium

Oct 31, 2024

BMS Anticipates New Opdivo Formulation Approval as CAR T, Targeted Therapy Sales Jump in Q3
Premium

Oct 31, 2024

Amgen Sees Strong Growth for Precision Oncology Drugs in Q3

Oct 29, 2024

Novartis Sees Steady Q3 Pluvicto Sales Growth as it Readies to Triple Eligible Population in 2025
Premium

Oct 29, 2024

Pfizer Highlights Upcoming Trial Readouts in Cancer as Oncology Unit Growth Continues in Q3
Premium

Oct 23, 2024

Roche Sees Strong Demand for Elevidys Gene Therapy Amid Steady Q3 Pharmaceutical Revenue Growth
Premium

Oct 15, 2024

Sales of J&J's Carvykti Surge Amid Expansion of Manufacturing Capacity
Premium